Carbonic Anhydrase Inhibitors
In the late 1930s, it was
reported that sulfanilamide and other N-unsubstituted
sulfonamides could induce di-uresis characterized by excretion of an alkaline
urine that is high in sodium bicarbonate. It was soon realized that these
compounds inhibited carbonic anhydrase,
an enzyme highly concentrated in renal tissue, and that this enzyme was
important for the tubular reabsorption of bicarbonate. The common structural
motif of carbonic anhydrase inhibitors is an unsubstituted sulfonamide moiety.
These findings led to the synthesis of a series of compounds capable of
inhibiting carbonic anhydrase, the most useful of which was acetazolamide (Diamox), which is considered the
prototype of this class of di-uretics. Although the clinical use of carbonic
anhydrase inhibitors has greatly diminished since the 1960s, when their use was
increasingly supplanted by the more po-tent thiazide diuretics (discussed
later), they have been vitally important in helping to delineate the
physiologi-cal role of carbonic anhydrase in electrolyte conserva-tion and
acid-base balance. Acetazolamide (Diamox),
dichlorphenamide (Daranide), and
methazolamide (Neptazane) are the
carbonic anhydrase inhibitors available in the United States.
Inhibition of proximal tubule brush border carbonic anhydrase
decreases bicarbonate reabsorption, and this accounts for their diuretic
effect. In addition, carbonic anhydrase
inhibitors affect both distal tubule and col-lecting duct H+ secretion
by inhibiting intracellular car-bonic anhydrase.
Renal excretion of NA+ , K+ , and HCO3- is increased by carbonic anhydrase inhibition. Diuresis following carbonic anhydrase inhibition consists
primarily of NA+ and HCO3- , with only a small
increase of Cl- excretion. This so-called bicarbonate diuresis is
unique to carbonic anhydrase inhibitors. The fractional excretion of NA+
is generally limited to 5%, as a consequence of down-stream compensatory NA+
reabsorption. Although dis-tal nephron sites recapture much of the NA+
, they pos-sess only a limited ability to absorb HCO3- .
Fractional K+ excretion, however, can be as much as 70%. Potassium loss is particularly marked
following carbonic anhydrase inhibition, both because of the presence of poorly reabsorbable HCO3-
accompanying NA+ and be-cause of the inhibition of the NA+
–H+ exchange mecha-nism. Elevated urinary HCO3-
excretion leads to the formation of alkaline urine and to metabolic acidosis as
a result of both HCO3- loss and impaired H+ secretion.
The main therapeutic use of carbonic anhydrase in-hibitors is not
for the production of diuresis but in the treatment of glaucoma. This is true especially of
the top-ically applied compound dorzolamide (Trusopt). Because the formation of aqueous humor in the eye
de-pends on carbonic anhydrase, acetazolamide has proved to be a useful adjunct
to the usual therapy for lowering intraocular pressure. Although acetazolamide
has been used in the treatment of epilepsy, particularly absence epilepsy, it
is not known whether the beneficial results are due to carbonic anhydrase
inhibition or to the re-sulting acidosis. Oral carbonic anhydrase inhibitors
are also useful in preventing or treating acute mountain sickness. Adverse
reactions are minor; they include loss of appetite, drowsiness, confusion, and
tingling in the extremities. Animal studies have shown some terato-genic
potential, so the use of carbonic anhydrase in-hibitors is not recommended
during the first trimester of pregnancy.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.